The additional investment brings Capra’s total ASPR funding to approximately $17 million and supports the company’s ongoing efforts to onshore the production of critical active pharmaceutical ingredients (APIs) currently sourced almost exclusively overseas. “Biotechnology offers tremendous power over traditional chemistry for making APIs because it is not limited by supply chains for key starting materials. With our initial ASPR funding, we successfully demonstrated that our modular reactors can produce high-quality APIs. The project validated Capra’s ability to deliver multiple APIs with quick turnaround and led to additional investment for additional APIs. Capra will now apply the rapid development and scale-up capabilities developed with X Development LLC (Mountain View, California) and Next Rung Technology (Somerville, Massachusetts) to additional critical pharmaceutical ingredients, bringing the company’s total number of API targets for domestic production to seven.